AKBM.OL OSL
Aker BioMarine AS
1W: -6.2%
1M: -23.5%
3M: +2.0%
YTD: +5.8%
1Y: +22.1%
3Y: +274.8%
5Y: +244.6%
kr 122.00 ($12.69)
+0.00 (+0.00%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$225M
+12.8% ▲
5Y CAGR: -4.9%
Gross Profit
$82M
+18.9% ▲
5Y CAGR: -5.6%
Operating Income
$21M
+424.6% ▲
5Y CAGR: +2.7%
Net Income
-$23M
-113.0% ▼
EPS (Diluted)
$-0.27
-68.8% ▼
EBITDA
$40M
+8.3% ▲
5Y CAGR: -10.1%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $262M | $277M | $335M | $199M | $225M |
| YoY Growth | -9.2% | +5.8% | +21.0% | -40.7% | +12.8% |
| Cost of Revenue | $174M | $162M | $222M | $130M | $142M |
| Gross Profit | $88M | $115M | $113M | $69M | $82M |
| Gross Margin | 33.6% | 41.4% | 33.7% | 34.7% | 36.6% |
| R&D Expenses | $3M | $4M | $690K | $4M | $0 |
| SG&A Expenses | $83M | $82M | $90M | $60M | $61M |
| Operating Expenses | $102M | $96M | $108M | $76M | $61M |
| Operating Income | $6M | $22M | $5M | -$6M | $21M |
| Operating Margin | 2.2% | 8.0% | 1.6% | -3.3% | 9.4% |
| Interest Expense | $14M | $20M | $33M | $2M | $16M |
| Income Before Tax | -$7M | $12M | -$34M | -$14M | -$3M |
| Tax Expense | $604K | $2M | -$25M | $100K | $0 |
| Net Income | -$8M | $10M | -$9M | $180M | -$23M |
| Net Margin | -3.1% | 3.6% | -2.7% | 90.6% | -10.5% |
| EPS (Diluted) | $-0.09 | $0.11 | $-0.37 | $-0.16 | $-0.27 |
| EBITDA | $59M | $82M | $50M | $37M | $40M |
| Shares Outstanding | 88M | 90M | 88M | 88M | 88M |